Published by Global Banking & Finance Review®
Posted on August 4, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on GoogleBioNTech's Q2 revenues doubled to 261 million euros due to increased COVID vaccine sales. The net loss improved significantly, and strategic acquisitions were made.
FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.
The company's quarterly net loss came in at 387 million euros, an improvement over a net loss of 808 million in the year-earlier period, which at the time was burdened by provisions for a settlement with the U.S. National Institutes of Health over vaccine royalty payments.
Lower operating expenses also helped reduce the second-quarter loss, it added.
BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.
BioNTech in June agreed to acquire domestic peer CureVac in a $1.25 billion share deal, boosting its work on new mRNA-based cancer treatments and quelling patent litigation brought by the takeover target.
That was shortly after Bristol Myers Squibb agreed to pay up to $11.1 billion for rights to jointly develop BioNTech's next-generation cancer immunotherapy.
($1 = 0.8654 euros)
(Reporting by Patricia Weiss and Ludwig Burger, Editing by Friederike Heine)
BioNTech reported second-quarter revenues of 261 million euros, which is approximately $302 million, more than doubling compared to the previous year.
The company's quarterly net loss was 387 million euros, which is an improvement from a net loss of 808 million euros in the same period last year.
BioNTech reiterated its guidance for 2025 revenues to be between 1.7 billion and 2.2 billion euros, a decrease from 2.75 billion euros last year.
In June, BioNTech agreed to acquire CureVac in a $1.25 billion share deal, which aims to enhance its work on new mRNA-based cancer treatments.
Bristol Myers Squibb agreed to pay up to $11.1 billion for rights to jointly develop BioNTech's next-generation cancer immunotherapy.
Explore more articles in the Finance category
